View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Christophe Chaput
  • Christophe Chaput
Christophe Chaput
  • Christophe Chaput
 PRESS RELEASE

Purchase of own shares

Purchase of own shares Paris, 6 October 2025, 6:00 p.m. PRESS RELEASE Eramet: Purchase of own shares Eramet announces the purchase of 9,900 of its own shares related to the allocation of bonus shares under the provisions of Articles L. 225-197-1 et seq. and L. 22-10-59 and L. 22-10-60 of the French Commercial Code (to cover the free allocation of shares to employees and corporate officer). Aggregated presentation per day and per market Name of issuer Identification code of issuer (Legal Entity Identifier) Day of transaction Identification code of financial instrument Aggre...

 PRESS RELEASE

Eramet : Rachat d'actions propres

Eramet : Rachat d'actions propres Paris, le 6 octobre 2025, 18h00 COMMUNIQUE DE PRESSE Eramet : Rachat d’actions propres Eramet annonce le rachat de 9 900 titres ayant pour objectif l'attribution gratuite d'actions dans le cadre des dispositions des articles L. 225-197-1 et suivants et L. 22-10-59 et L. 22-10-60 du code de commerce (couverture d’attribution gratuite d’actions aux salariés et au mandataire social). Présentation agrégée par jour et par marché Nom del'émetteur Code Identifiant de l'émetteur Jour de la transaction Code identifiantde l’instrumentfinancier Vol...

Carole Braudeau
  • Carole Braudeau

Credit Morning 10/06/2025

Seb issues a second major profit warning for this year|Isabel Marant steps back from designing collections|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 06/10/2025

Seb fait un 2e gros profit warning pour cette année|Isabel Marant se met en retrait de la conception des collections|

 PRESS RELEASE

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction...

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical remission in particip...

 PRESS RELEASE

Eramet : Informations relatives au nombre total de droits de vote et d...

Eramet : Informations relatives au nombre total de droits de vote et d’actions au 30 septembre 2025 Dénomination sociale de l'émetteur : ERAMET SA10 boulevard de Grenelle75015 Paris632 045 381 RCS PARIS Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 223-8 II du code de commerce et l’article 223-16 du règlement général de l’Autorité des marchés financiers N° LEI : 549300LUH78PG2MP6N64 Date d'arrêté des informationsNombre total d'actions composant le capitalNombre total de droits de vote 30 septembre 202528 755 047Nombre de droits de vote th...

 PRESS RELEASE

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Res...

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch